Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/9927
Animal models of arrhythmogenic right ventricular cardiomyopathy: what have we learned and where do we go? Insight for therapeutics
Basic Res Cardiol. 2017; 112(5):50
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare genetically-determined cardiac heart muscle disorder characterized by fibro-fatty replacement of the myocardium that results in heart failure and sudden cardiac death (SCD), predominantly in young males. The disease is often caused by mutations in genes encoding proteins of the desmosomal complex, with a significant minority caused by mutations in non-desmosomal proteins. Existing treatment options are based on SCD prevention with the implantable cardioverter defibrillator, antiarrhythmic drugs, and anti-heart failure medication. Heart transplantation may also be required and there is currently no cure. Several genetically modified animal models have been developed to characterize the disease, assess its progression, and determine the influence of potential environmental factors. These models have also been very valuable for translational therapeutic approaches, to screen new treatment options that prevent and/or reverse the disease. Here, we review the available ARVC animal models reported to date, highlighting the most important pathophysiological findings and discussing the effect of treatments tested so far in this setting. We also describe gaps in our knowledge of the disease, with the goal of stimulating research and improving patient outcomes.
Animals | Anti-Arrhythmia Agents | Arrhythmogenic Right Ventricular Dysplasia | Cardiotonic Agents | Defibrillators, Implantable | Disease Models, Animal | Genetic Predisposition to Disease | Humans | Mutation | Myocardium | Phenotype | Physical Exertion | Electric Countershock
Files in this item
- AnimalModelsArrhythmogenicRight ...